Literature DB >> 24492323

B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies.

K Bojarczuk1, M Siernicka1, M Dwojak1, M Bobrowicz1, B Pyrzynska1, P Gaj1, M Karp2, K Giannopoulos2, D G Efremov3, C Fauriat4, J Golab5, M Winiarska1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24492323     DOI： 10.1038/leu.2014.12

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

Authors:  Sarah E M Herman; Amber L Gordon; Amy J Wagner; Nyla A Heerema; Weiqiang Zhao; Joseph M Flynn; Jeffrey Jones; Leslie Andritsos; Kamal D Puri; Brian J Lannutti; Neill A Giese; Xiaoli Zhang; Lai Wei; John C Byrd; Amy J Johnson
Journal:  Blood       Date:  2010-06-03       Impact factor: 22.113

2.  The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.

Authors:  Julia Hoellenriegel; Sarah A Meadows; Mariela Sivina; William G Wierda; Hagop Kantarjian; Michael J Keating; Neill Giese; Susan O'Brien; Albert Yu; Langdon L Miller; Brian J Lannutti; Jan A Burger
Journal:  Blood       Date:  2011-07-29       Impact factor: 22.113

Review 3.  Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors.

Authors:  M A Kharfan-Dabaja; W G Wierda; L J N Cooper
Journal:  Leukemia       Date:  2013-10-25       Impact factor: 11.528

4.  Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Authors:  R Eric Davis; Vu N Ngo; Georg Lenz; Pavel Tolar; Ryan M Young; Paul B Romesser; Holger Kohlhammer; Laurence Lamy; Hong Zhao; Yandan Yang; Weihong Xu; Arthur L Shaffer; George Wright; Wenming Xiao; John Powell; Jian-Kang Jiang; Craig J Thomas; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Nathalie A Johnson; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Wyndham H Wilson; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Dennis D Weisenburger; Wing C Chan; Susan K Pierce; Louis M Staudt
Journal:  Nature       Date:  2010-01-07       Impact factor: 49.962

5.  Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling.

Authors:  Marcus Dühren-von Minden; Rudolf Übelhart; Dunja Schneider; Thomas Wossning; Martina P Bach; Maike Buchner; Daniel Hofmann; Elena Surova; Marie Follo; Fabian Köhler; Hedda Wardemann; Katja Zirlik; Hendrik Veelken; Hassan Jumaa
Journal:  Nature       Date:  2012-09-13       Impact factor: 49.962

6.  Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.

Authors:  S Gobessi; L Laurenti; P G Longo; L Carsetti; V Berno; S Sica; G Leone; D G Efremov
Journal:  Leukemia       Date:  2008-12-18       Impact factor: 11.528

7.  PI3 kinase signals BCR-dependent mature B cell survival.

Authors:  Lakshmi Srinivasan; Yoshiteru Sasaki; Dinis Pedro Calado; Baochun Zhang; Ji Hye Paik; Ronald A DePinho; Jeffrey L Kutok; John F Kearney; Kevin L Otipoby; Klaus Rajewsky
Journal:  Cell       Date:  2009-10-30       Impact factor: 41.582

8.  SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.

Authors:  Linfeng Chen; Stefano Monti; Przemyslaw Juszczynski; Jing Ouyang; Bjoern Chapuy; Donna Neuberg; John G Doench; Agata M Bogusz; Thomas M Habermann; Ahmet Dogan; Thomas E Witzig; Jeffery L Kutok; Scott J Rodig; Todd Golub; Margaret A Shipp
Journal:  Cancer Cell       Date:  2013-06-10       Impact factor: 31.743

9.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

Review 10.  Molecular mechanisms of the antitumor effects of anti-CD20 antibodies.

Authors:  Magdalena Winiarska; Eliza Glodkowska-Mrowka; Jacek Bil; Jakub Golab
Journal:  Front Biosci (Landmark Ed)       Date:  2011-01-01
View more
  24 in total

Review 1.  Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion.

Authors:  Deborah M Stephens; Stephen E Spurgeon
Journal:  Ther Adv Hematol       Date:  2015-10

Review 2.  The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Authors:  Adrian Wiestner
Journal:  Haematologica       Date:  2015-12       Impact factor: 9.941

Review 3.  Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.

Authors:  Madeline Waldron; Allison Winter; Brian T Hill
Journal:  Clin Pharmacokinet       Date:  2017-11       Impact factor: 6.447

4.  Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.

Authors:  Emily M McWilliams; Christopher R Lucas; Timothy Chen; Bonnie K Harrington; Ronni Wasmuth; Amanda Campbell; Kerry A Rogers; Carolyn M Cheney; Xiaokui Mo; Leslie A Andritsos; Farrukh T Awan; Jennifer Woyach; William E Carson; Jonathan Butchar; Susheela Tridandapani; Erin Hertlein; Carlos E Castro; Natarajan Muthusamy; John C Byrd
Journal:  Blood Adv       Date:  2019-02-12

5.  Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.

Authors:  Fabio Da Roit; Patrick J Engelberts; Ronald P Taylor; Esther C W Breij; Giuseppe Gritti; Alessandro Rambaldi; Martino Introna; Paul W H I Parren; Frank J Beurskens; Josée Golay
Journal:  Haematologica       Date:  2014-10-24       Impact factor: 9.941

Review 6.  Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.

Authors:  Andrew Aw; Jennifer R Brown
Journal:  Drugs Aging       Date:  2017-07       Impact factor: 3.923

7.  Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.

Authors:  Zijun Y Xu-Monette; Ling Li; John C Byrd; Kausar J Jabbar; Ganiraju C Manyam; Charlotte Maria de Winde; Michiel van den Brand; Alexandar Tzankov; Carlo Visco; Jing Wang; Karen Dybkaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Michael B Møller; Ben M Parsons; Jane N Winter; Michael Wang; Frederick B Hagemeister; Miguel A Piris; J Han van Krieken; L Jeffrey Medeiros; Yong Li; Annemiek B van Spriel; Ken H Young
Journal:  Blood       Date:  2016-10-19       Impact factor: 22.113

8.  Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model.

Authors:  Yaya Chu; Sanghoon Lee; Tishi Shah; Changhong Yin; Matthew Barth; Rodney R Miles; Janet Ayello; Erin Morris; Lauren Harrison; Carmella Van de Ven; Paul Galardy; Stanton C Goldman; Megan S Lim; Michelle Hermiston; Linda M McAllister-Lucas; Lisa Giulino-Roth; Sherrie L Perkins; Mitchell S Cairo
Journal:  Oncoimmunology       Date:  2018-10-11       Impact factor: 8.110

9.  Adenanthin, a new inhibitor of thiol-dependent antioxidant enzymes, impairs the effector functions of human natural killer cells.

Authors:  Marta Siernicka; Magdalena Winiarska; Malgorzata Bajor; Malgorzata Firczuk; Angelika Muchowicz; Malgorzata Bobrowicz; Cyril Fauriat; Jakub Golab; Daniel Olive; Radoslaw Zagozdzon
Journal:  Immunology       Date:  2015-07-08       Impact factor: 7.397

10.  Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.

Authors:  Martin Skarzynski; Carsten U Niemann; Yuh Shan Lee; Sabrina Martyr; Irina Maric; Dalia Salem; Maryalice Stetler-Stevenson; Gerald E Marti; Katherine R Calvo; Constance Yuan; Janet Valdez; Susan Soto; Mohammed Z H Farooqui; Sarah E M Herman; Adrian Wiestner
Journal:  Clin Cancer Res       Date:  2015-08-17       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.